These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 27108679)

  • 1. Molecular and crystal structure of praziquantel. Spectroscopic properties and crystal polymorphism.
    Borrego-Sánchez A; Viseras C; Aguzzi C; Sainz-Díaz CI
    Eur J Pharm Sci; 2016 Sep; 92():266-75. PubMed ID: 27108679
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular modeling and infrared and Raman spectroscopy of the crystal structure of the chiral antiparasitic drug Praziquantel.
    Borrego-Sánchez A; Hernández-Laguna A; Sainz-Díaz CI
    J Mol Model; 2017 Apr; 23(4):106. PubMed ID: 28275906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational polymorphic changes in the crystal structure of the chiral antiparasitic drug praziquantel and interactions with calcium carbonate.
    Borrego-Sánchez A; Carazo E; Albertini B; Passerini N; Perissutti B; Cerezo P; Viseras C; Hernández-Laguna A; Aguzzi C; Sainz-Díaz CI
    Eur J Pharm Biopharm; 2018 Nov; 132():180-191. PubMed ID: 30267834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the phase diagrams of chiral praziquantel.
    Liu Y; Wang X; Wang JK; Ching CB
    Chirality; 2006 May; 18(4):259-64. PubMed ID: 16521119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Praziquantel and schistosomiasis.
    Dömling A; Khoury K
    ChemMedChem; 2010 Sep; 5(9):1420-34. PubMed ID: 20677314
    [No Abstract]   [Full Text] [Related]  

  • 6. [Progress of research on preparation and application of praziquantel].
    Wu DZ; Ma Z; Liu YF; Zhu WF; Ning A
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2013 Apr; 25(2):194-6. PubMed ID: 23894845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theoretical and experimental study of a praziquantel and beta-cyclodextrin inclusion complex using molecular mechanic calculations and H1-nuclear magnetic resonance.
    de Jesus MB; de Matos Alves Pinto L; Fraceto LF; Takahata Y; Lino AC; Jaime C; de Paula E
    J Pharm Biomed Anal; 2006 Jun; 41(4):1428-32. PubMed ID: 16678375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing the usefulness of cross dehydrogenative coupling reactions with a removable protecting group.
    Tsang AS; Ingram K; Keiser J; Hibbert DB; Todd MH
    Org Biomol Chem; 2013 Aug; 11(30):4921-4. PubMed ID: 23820826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and relative bioavailability of praziquantel in healthy water buffalo after oral and intramuscular administration.
    Sun Y; Bu SJ
    J Vet Pharmacol Ther; 2012 Dec; 35(6):618-22. PubMed ID: 22239339
    [No Abstract]   [Full Text] [Related]  

  • 10. Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance.
    Doenhoff MJ; Pica-Mattoccia L
    Expert Rev Anti Infect Ther; 2006 Apr; 4(2):199-210. PubMed ID: 16597202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schistosomicidal effect of the anti-inflammatory drug diclofenac and its structural correlation with praziquantel.
    Carvalho AA; Mafud AC; Pinto PL; Mascarenhas YP; de Moraes J
    Int J Antimicrob Agents; 2014 Oct; 44(4):372-4. PubMed ID: 25178921
    [No Abstract]   [Full Text] [Related]  

  • 12. Resolution of praziquantel.
    Woelfle M; Seerden JP; de Gooijer J; Pouwer K; Olliaro P; Todd MH
    PLoS Negl Trop Dis; 2011 Sep; 5(9):e1260. PubMed ID: 21949890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of a new antischistosomally active and toxicologically tolerant C-12 monothione surrogate of the universal antihelmintic praziquantel.
    Abo-Ghalia MH; Soliman AM
    Acta Pol Pharm; 2002; 59(4):313-20. PubMed ID: 12403307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A high-performance liquid chromatography and nuclear magnetic resonance spectroscopy-based analysis of commercially available praziquantel tablets.
    Li J; Wang Y; Fenwick A; Clayton TA; Lau YY; Legido-Quigley C; Lindon JC; Utzinger J; Holmes E
    J Pharm Biomed Anal; 2007 Oct; 45(2):263-7. PubMed ID: 17659859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ca2+ signalling, voltage-gated Ca2+ channels and praziquantel in flatworm neuromusculature.
    Greenberg RM
    Parasitology; 2005; 131 Suppl():S97-108. PubMed ID: 16569296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of praziquantel in kingfish Seriola lalandi.
    Tubbs L; Mathieson T; Tingle M
    Dis Aquat Organ; 2008 Jan; 78(3):225-33. PubMed ID: 18380221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of implant diameter, drug loading and end-capping on praziquantel release from PCL implants.
    Li C; Cheng L; Zhang Y; Guo S; Wu W
    Int J Pharm; 2010 Feb; 386(1-2):23-9. PubMed ID: 19895876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Praziquantel derivatives I: Modification of the aromatic ring.
    Ronketti F; Ramana AV; Chao-Ming X; Pica-Mattoccia L; Cioli D; Todd MH
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4154-7. PubMed ID: 17555960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo evaluation of praziquantel loaded implants based on PEG/PCL blends.
    Cheng L; Lei L; Guo S
    Int J Pharm; 2010 Mar; 387(1-2):129-38. PubMed ID: 20005928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment.
    de Souza AL; Andreani T; de Oliveira RN; Kiill CP; dos Santos FK; Allegretti SM; Chaud MV; Souto EB; Silva AM; Gremião MP
    Int J Pharm; 2014 Mar; 463(1):31-7. PubMed ID: 24370839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.